Neonatology research faces stagnation despite rising survival rates
While medical advancements have significantly improved survival rates for premature babies, research into specialized treatments has stagnated. Dr. Carmen Pallás, Head of Neonatology at Hospital 12 de Octubre in Madrid, notes that many newborns still rely on medications originally developed for adults or older children.
In Spain, approximately 30,000 premature babies are born annually, with survival rates reaching 95%. Despite these successes, experts warn that the field of neonatology faces discrimination from the pharmaceutical industry, resulting in limited investment for new drugs and technology specifically designed for newborns.